retatrutide weight loss clinical data What GLP‑3 Really Is: Triple‑Receptor Drug A new weight-loss drug called

Funding This work was carried out with the financial support of Medical University of Lodz

TG is also significantly associated with NAFLD 16

Side effects Nausea (38-43% depending on dose most common side effect, typically peaks during titration and improves after 8-12 weeks of gradual dose escalation) Diarrhea (33-35% dose-dependent, usually mild to moderate severity, manageable with dietary adjustments) Vomiting (20-21% more common at higher doses and during rapid titration, often resolves with slower dose escalation) Constipation (22-25% can occur alternately with diarrhea during dose adjustment periods) Decreased appetite (18-19% related to GLP-1 mechanism of action, distinct from nausea-related food avoidance) Dysesthesia (8.8% at 9 mg, 20.9% at 12 mg vs 0.7% placebo NEW safety signal identified in Phase 3 TRIUMPH-4, not observed in Phase 2

Enhances absorption: BioPerine (black pepper extract) improves the bioavailability and efficacy of the other ingredients

doi: 10.1007/s00125-018-4729-5

GLP-1 constipation is a mechanical consequence of how the drug does its job